Drs Sandhya Srinivas and Shilpa Gupta discuss castration-resistant prostate cancer and the sequence, method of therapy, and specific patient populations in which these drugs will be most effective.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988733). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Patient-Reported Outcomes Following Enzalutamide or Placebo in Men With Non-Metastatic, Castration-Resistant Prostate Cancer (PROSPER): A Multicentre, Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30770294/
Apalutamide and Overall Survival in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/32907777/
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/30763142/
Long-term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From the ARAMIS Rollover Study. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.147
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial https://pubmed.ncbi.nlm.nih.gov/29384722/
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition) https://clinicaltrials.gov/ct2/show/NCT04720157
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/31566937/
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval https://pubmed.ncbi.nlm.nih.gov/35553387/
